Eli Lilly/$LLY
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Eli Lilly
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Ticker
$LLY
Sector
Primary listing
NYSE
Employees
47,000
Headquarters
Website
Eli Lilly Metrics
BasicAdvanced
$972B
53.09
$20.44
0.39
$6.00
0.55%
Price and volume
Market cap
$972B
Beta
0.39
52-week high
$1,133.95
52-week low
$623.78
Average daily volume
3.1M
Dividend rate
$6.00
Financial strength
Current ratio
1.546
Quick ratio
0.724
Long term debt to equity
171.664
Total debt to equity
178.516
Dividend payout ratio (TTM)
28.28%
Interest coverage (TTM)
26.44%
Profitability
EBITDA (TTM)
28,728.6
Gross margin (TTM)
83.03%
Net profit margin (TTM)
30.99%
Operating margin (TTM)
45.16%
Effective tax rate (TTM)
18.18%
Revenue per employee (TTM)
$1,260,000
Management effectiveness
Return on assets (TTM)
17.83%
Return on equity (TTM)
96.47%
Valuation
Price to earnings (TTM)
53.086
Price to revenue (TTM)
16.358
Price to book
40.86
Price to tangible book (TTM)
84.91
Price to free cash flow (TTM)
138.512
Free cash flow yield (TTM)
0.72%
Free cash flow per share (TTM)
7.835
Dividend yield (TTM)
0.55%
Forward dividend yield
0.55%
Growth
Revenue change (TTM)
45.41%
Earnings per share change (TTM)
121.01%
3-year revenue growth (CAGR)
26.66%
10-year revenue growth (CAGR)
11.67%
3-year earnings per share growth (CAGR)
45.39%
10-year earnings per share growth (CAGR)
24.87%
3-year dividend per share growth (CAGR)
15.24%
10-year dividend per share growth (CAGR)
11.29%
What the Analysts think about Eli Lilly
Analyst ratings (Buy, Hold, Sell) for Eli Lilly stock.
Eli Lilly Financial Performance
Revenues and expenses
Eli Lilly Earnings Performance
Company profitability
Eli Lilly News
AllArticlesVideos
Novo Nordisk and Eli Lilly can both gain GLP-1 market share this year, says Citi's Meacham
CNBC Television·5 hours ago
Eli Lilly Stock Back In Focus After Long Slumber
Investors Business Daily·6 hours ago
Eli Lilly Stock Broke Out Following Plan To Acquire Ventyx Biosciences
Investors Business Daily·9 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Eli Lilly stock?
Eli Lilly (LLY) has a market cap of $972B as of January 10, 2026.
What is the P/E ratio for Eli Lilly stock?
The price to earnings (P/E) ratio for Eli Lilly (LLY) stock is 53.09 as of January 10, 2026.
Does Eli Lilly stock pay dividends?
Yes, the Eli Lilly (LLY) stock pays dividends to shareholders. As of January 10, 2026, the dividend rate is $6 and the yield is 0.55%. Eli Lilly has a payout ratio of 28.28% on a trailing twelve-month basis.
When is the next Eli Lilly dividend payment date?
The next Eli Lilly (LLY) dividend payment is scheduled for March 10, 2026.
What is the beta indicator for Eli Lilly?
Eli Lilly (LLY) has a beta rating of 0.39. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.